Publication

Targeted induction of apoptosis for cancer therapy: current progress and prospects

Bremer, E., van Dam, G., Kroesen, B. J., de Leij, L. & Helfrich, W., Aug-2006, In : TRENDS IN MOLECULAR MEDICINE. 12, 8, p. 382-393 12 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Bremer, E., van Dam, G., Kroesen, B. J., de Leij, L., & Helfrich, W. (2006). Targeted induction of apoptosis for cancer therapy: current progress and prospects. TRENDS IN MOLECULAR MEDICINE, 12(8), 382-393. https://doi.org/10.1016/j.molmed.2006.06.002

Author

Bremer, Edwin ; van Dam, Go ; Kroesen, Bart Jan ; de Leij, Lou ; Helfrich, Wijnand. / Targeted induction of apoptosis for cancer therapy : current progress and prospects. In: TRENDS IN MOLECULAR MEDICINE. 2006 ; Vol. 12, No. 8. pp. 382-393.

Harvard

Bremer, E, van Dam, G, Kroesen, BJ, de Leij, L & Helfrich, W 2006, 'Targeted induction of apoptosis for cancer therapy: current progress and prospects', TRENDS IN MOLECULAR MEDICINE, vol. 12, no. 8, pp. 382-393. https://doi.org/10.1016/j.molmed.2006.06.002

Standard

Targeted induction of apoptosis for cancer therapy : current progress and prospects. / Bremer, Edwin; van Dam, Go; Kroesen, Bart Jan; de Leij, Lou; Helfrich, Wijnand.

In: TRENDS IN MOLECULAR MEDICINE, Vol. 12, No. 8, 08.2006, p. 382-393.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. TRENDS IN MOLECULAR MEDICINE. 2006 Aug;12(8):382-393. https://doi.org/10.1016/j.molmed.2006.06.002


BibTeX

@article{346cb422d97c4fc1ab17ad4c8f6c43eb,
title = "Targeted induction of apoptosis for cancer therapy: current progress and prospects",
abstract = "Important breakthroughs in cancer therapy include clinical application of antibodies, such as Rituximab, and small inhibitory molecules, such as Iressa and Velcade. In addition, recent reports have indicated the therapeutic potential of physiological pro-apoptotic proteins such as TRAIL and galectin-1. Although unrelated at first glance, each strategy relies on the deliberate and selective induction of apoptosis in malignant cells. Importantly, therapy-resistance in cancer is frequently associated with de-regulation in the mechanisms that control apoptosis. However, cancer cells are often reliant on these molecular aberrations for survival. Therefore, selective induction of apoptosis in cancer cells but not normal cells seems feasible. Here, we review recent progress and prospects of selected novel anti-cancer approaches that specifically target and sensitize cancer cells to apoptosis.",
keywords = "HISTONE DEACETYLASE INHIBITORS, CHRONIC LYMPHOCYTIC-LEUKEMIA, ACUTE MYELOID-LEUKEMIA, STRAIL FUSION PROTEIN, RECEPTOR-MEDIATED APOPTOSIS, SMALL-MOLECULE ANTAGONISTS, BCL-2 FAMILY PROTEINS, INDUCIBLE-FACTOR-I, HUMAN TUMOR-CELLS, ANTIPROLIFERATIVE CYTOKINE",
author = "Edwin Bremer and {van Dam}, Go and Kroesen, {Bart Jan} and {de Leij}, Lou and Wijnand Helfrich",
year = "2006",
month = "8",
doi = "10.1016/j.molmed.2006.06.002",
language = "English",
volume = "12",
pages = "382--393",
journal = "TRENDS IN MOLECULAR MEDICINE",
issn = "1471-4914",
publisher = "ELSEVIER SCI LTD",
number = "8",

}

RIS

TY - JOUR

T1 - Targeted induction of apoptosis for cancer therapy

T2 - current progress and prospects

AU - Bremer, Edwin

AU - van Dam, Go

AU - Kroesen, Bart Jan

AU - de Leij, Lou

AU - Helfrich, Wijnand

PY - 2006/8

Y1 - 2006/8

N2 - Important breakthroughs in cancer therapy include clinical application of antibodies, such as Rituximab, and small inhibitory molecules, such as Iressa and Velcade. In addition, recent reports have indicated the therapeutic potential of physiological pro-apoptotic proteins such as TRAIL and galectin-1. Although unrelated at first glance, each strategy relies on the deliberate and selective induction of apoptosis in malignant cells. Importantly, therapy-resistance in cancer is frequently associated with de-regulation in the mechanisms that control apoptosis. However, cancer cells are often reliant on these molecular aberrations for survival. Therefore, selective induction of apoptosis in cancer cells but not normal cells seems feasible. Here, we review recent progress and prospects of selected novel anti-cancer approaches that specifically target and sensitize cancer cells to apoptosis.

AB - Important breakthroughs in cancer therapy include clinical application of antibodies, such as Rituximab, and small inhibitory molecules, such as Iressa and Velcade. In addition, recent reports have indicated the therapeutic potential of physiological pro-apoptotic proteins such as TRAIL and galectin-1. Although unrelated at first glance, each strategy relies on the deliberate and selective induction of apoptosis in malignant cells. Importantly, therapy-resistance in cancer is frequently associated with de-regulation in the mechanisms that control apoptosis. However, cancer cells are often reliant on these molecular aberrations for survival. Therefore, selective induction of apoptosis in cancer cells but not normal cells seems feasible. Here, we review recent progress and prospects of selected novel anti-cancer approaches that specifically target and sensitize cancer cells to apoptosis.

KW - HISTONE DEACETYLASE INHIBITORS

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - ACUTE MYELOID-LEUKEMIA

KW - STRAIL FUSION PROTEIN

KW - RECEPTOR-MEDIATED APOPTOSIS

KW - SMALL-MOLECULE ANTAGONISTS

KW - BCL-2 FAMILY PROTEINS

KW - INDUCIBLE-FACTOR-I

KW - HUMAN TUMOR-CELLS

KW - ANTIPROLIFERATIVE CYTOKINE

U2 - 10.1016/j.molmed.2006.06.002

DO - 10.1016/j.molmed.2006.06.002

M3 - Review article

VL - 12

SP - 382

EP - 393

JO - TRENDS IN MOLECULAR MEDICINE

JF - TRENDS IN MOLECULAR MEDICINE

SN - 1471-4914

IS - 8

ER -

ID: 4472775